Eupraxia Pharmaceuticals Inc.
EPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $274,953 | $206,855 | $117,051 | $112,923 |
| - Cash | $123,953 | $19,766 | $27,455 | $33,101 |
| + Debt | $237 | $35 | $53 | $72 |
| Enterprise Value | $151,237 | $187,125 | $89,649 | $79,894 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$8,725 | -$11,835 | -$9,567 | -$10,751 |
| % Margin | – | – | – | – |
| Net Income | -$8,852 | -$11,909 | -$9,631 | -$10,799 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.26 | -0.33 | -0.3 | -0.21 |
| % Growth | 21.2% | -10% | -42.9% | – |
| Operating Cash Flow | -$4,507 | -$8,315 | -$6,003 | -$5,972 |
| Capital Expenditures | -$60 | -$166 | -$169 | -$44 |
| Free Cash Flow | -$4,567 | -$8,481 | -$6,172 | -$6,017 |